Home >> Pharmaceuticals >> Food & Beverage >>

NuCana BioMed Limited - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 32 | Code: MRS - 35140

NuCana BioMed Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘NuCana BioMed Limited - Product Pipeline Review - 2015’, provides an overview of the NuCana BioMed Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NuCana BioMed Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NuCana BioMed Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NuCana BioMed Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the NuCana BioMed Limited’s pipeline products

Reasons to buy

- Evaluate NuCana BioMed Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NuCana BioMed Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NuCana BioMed Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NuCana BioMed Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NuCana BioMed Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NuCana BioMed Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
NuCana BioMed Limited Snapshot 5
NuCana BioMed Limited Overview 5
Key Information 5
Key Facts 5
NuCana BioMed Limited - Research and Development Overview 6
Key Therapeutic Areas 6
NuCana BioMed Limited - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
NuCana BioMed Limited - Pipeline Products Glance 11
NuCana BioMed Limited - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
NuCana BioMed Limited - Early Stage Pipeline Products 13
IND/CTA Filed Products/Combination Treatment Modalities 13
Preclinical Products/Combination Treatment Modalities 14
NuCana BioMed Limited - Drug Profiles 15
NUC-1031 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
NUC-3373 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
NUC-7738 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NUC-4545 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NUC-5435 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NUC-6285 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NUC-9000 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NUC-9324 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
NuCana BioMed Limited - Pipeline Analysis 24
NuCana BioMed Limited - Pipeline Products by Target 24
NuCana BioMed Limited - Pipeline Products by Route of Administration 25
NuCana BioMed Limited - Pipeline Products by Molecule Type 26
NuCana BioMed Limited - Pipeline Products by Mechanism of Action 27
NuCana BioMed Limited - Recent Pipeline Updates 28
NuCana BioMed Limited - Dormant Projects 29
NuCana BioMed Limited - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 31
Disclaimer 32

List of Tables
NuCana BioMed Limited, Key Information 5
NuCana BioMed Limited, Key Facts 5
NuCana BioMed Limited - Pipeline by Indication, 2015 8
NuCana BioMed Limited - Pipeline by Stage of Development, 2015 9
NuCana BioMed Limited - Monotherapy Products in Pipeline, 2015 10
NuCana BioMed Limited - Phase II, 2015 11
NuCana BioMed Limited - Phase I, 2015 12
NuCana BioMed Limited - IND/CTA Filed, 2015 13
NuCana BioMed Limited - Preclinical, 2015 14
NuCana BioMed Limited - Pipeline by Target, 2015 24
NuCana BioMed Limited - Pipeline by Route of Administration, 2015 25
NuCana BioMed Limited - Pipeline by Molecule Type, 2015 26
NuCana BioMed Limited - Pipeline Products by Mechanism of Action, 2015 27
NuCana BioMed Limited - Recent Pipeline Updates, 2015 28
NuCana BioMed Limited - Dormant Developmental Projects,2015 29

List of Figures
NuCana BioMed Limited - Pipeline by Top 10 Indication, 2015 7
NuCana BioMed Limited - Pipeline by Stage of Development, 2015 9
NuCana BioMed Limited - Monotherapy Products in Pipeline, 2015 10
NuCana BioMed Limited - Pipeline by Top 10 Target, 2015 24
NuCana BioMed Limited - Pipeline by Top 10 Route of Administration, 2015 25
NuCana BioMed Limited - Pipeline by Top 10 Molecule Type, 2015 26
NuCana BioMed Limited - Pipeline Products by Top 10 Mechanism of Action, 2015 27

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing